India's Narcotics Control Bureau (NCB) has ordered all entities handling the chemical 2-Bromo-4-Methylpropiophenone to register with the agency [1].
This regulatory move aims to curb the illegal production of mephedrone, a psychotropic drug frequently manufactured by drug cartels [1]. By tracking the movement of this specific precursor chemical, the government intends to disrupt the supply chains used by illicit laboratories.
The NCB added 2-Bromo-4-Methylpropiophenone to the country's list of controlled substances [1]. This designation means that any company, laboratory, or individual transporting or storing the chemical must now maintain official registration and adhere to strict reporting guidelines [2].
Officials said the chemical is a key ingredient in the synthesis of mephedrone [1]. The drug has become a target of enforcement due to its misuse and the role of organized crime networks in its distribution across the region [2].
The new mandate applies to all entities operating within India that handle the substance [1]. Failure to register may lead to legal penalties under the country's narcotics laws, as the agency seeks to close loopholes that allow precursors to leak from legal industrial channels into the black market [2].
This action follows a broader strategy by New Delhi to tighten oversight on dual-use chemicals, substances that have legitimate industrial applications but can also be diverted for drug production [1].
“The NCB added 2-Bromo-4-Methylpropiophenone to the country's list of controlled substances.”
The reclassification of 2-Bromo-4-Methylpropiophenone signals a shift toward a 'precursor-first' enforcement strategy in India. By targeting the raw materials rather than just the finished product, the NCB is attempting to prevent the manufacture of synthetic stimulants before they reach the street level, placing a higher compliance burden on the legitimate chemical industry to prevent diversion.
